Arsenal Biosciences, a South San Francisco–based biotech startup specializing in cell therapy, is laying off around half of its workforce, just one year after raising one of the largest funding rounds in the sector.
According to a Worker Adjustment and Retraining Notification (WARN) filing, about 100 employees will lose their jobs, including staff at the company’s Oyster Point headquarters and remote workers. The layoffs, effective November 14, come as the firm works to extend its financial runway and shift focus from early-stage cancer research to the more demanding stage of clinical trials.
The decision underscores how volatile the biotech sector remains. Even with high-profile investors and hundreds of millions raised, companies are increasingly forced to trim operations in order to prioritize the costly journey of developing therapies for patients.
Who’s Affected
The WARN filing shows that scientists and research staff bore the brunt of the cuts, although leadership positions were not spared. Several director-level managers and two vice presidents are also departing. None of the employees impacted are unionized.
The job losses highlight a difficult reality: even promising startups with deep financial backing must carefully balance scientific ambition with operational costs. For cell therapy companies, this balancing act is especially difficult given the steep expenses of moving from laboratory breakthroughs into real-world clinical studies.
Arsenal’s Scientific Focus
Arsenal Biosciences’ leading candidate is a cell therapy being tested for kidney cancer. In addition to this flagship program, the company is advancing two other in-house therapies and collaborating with pharmaceutical heavyweight Bristol Myers Squibb on two further projects.
Its mission lies in reprogramming immune cells to fight tumors and other diseases. This area of science, while offering enormous promise, has faced hurdles across the industry. Complex engineering, stringent regulatory pathways, and the unpredictable outcomes of clinical studies all make cell therapy a challenging field to navigate.
Industry-Wide Setbacks
The timing of Arsenal’s layoffs reflects broader pressures in the biotech sector. After a surge of investment during the COVID-19 pandemic, funding for life sciences has slowed dramatically. Venture capital firms have tightened their spending, and companies are under pressure to prove their therapies can succeed in clinical settings.
Cell therapy startups in particular have been hit hard. Over the past two years, several companies have reported layoffs, mergers, or complete shutdowns. Even with strong science, the sector is struggling to secure the resources necessary to bridge the gap between research and commercialization.
The Bay Area, once considered one of the world’s hottest biotech hubs, has seen multiple rounds of cuts in recent months, reflecting an industry-wide retreat from the aggressive growth seen earlier in the decade.
From Heavy Investment to Cost-Cutting
Arsenal’s announcement comes as a surprise to many, given its massive fundraising success. In 2022, the company secured $220 million in a Series B round, followed by a $325 million Series C round in September 2023. These deals pushed Arsenal’s total fundraising past the half-billion-dollar mark, with major investors including Kleiner Perkins, Nvidia’s venture arm, and SoftBank Vision Fund 2.
The expectation was that such strong financial backing would accelerate growth and expand research. Instead, the company is pivoting to a leaner model, focusing resources on getting its therapies through clinical testing. This shift marks a transition from investor-fueled expansion to financial discipline, a trend becoming increasingly common in biotech.
Employee Reactions
The layoffs have sparked disappointment among staff, many of whom expressed surprise on professional networks such as LinkedIn. Some noted the irony of job cuts occurring just a year after the company’s record-breaking Series C raise. Others emphasized pride in the progress made during their tenure, while acknowledging the unpredictable nature of biotech careers.
For many employees, the cuts represent not only the loss of a job but also a disruption in working on cutting-edge science that had seemed so promising only months before.
Balancing Science and Sustainability
Arsenal’s restructuring illustrates the challenge biotech startups face when transitioning to clinical trials. Beyond research, this stage demands major investments in manufacturing processes, patient recruitment, and regulatory compliance. Without careful planning, even well-capitalized companies risk running out of resources before their therapies can demonstrate real-world success.
By cutting half of its staff, Arsenal aims to preserve its funding and direct resources where they matter most: advancing its most promising therapies through early clinical stages. Whether this strategy pays off will depend on trial outcomes in the coming years.
